AZN.UK

10,510

-1.37%↓

GSK

1,406

-1.37%↓

AZN.UK

10,510

-1.37%↓

GSK

1,406

-1.37%↓

AZN.UK

10,510

-1.37%↓

GSK

1,406

-1.37%↓

AZN.UK

10,510

-1.37%↓

GSK

1,406

-1.37%↓

AZN.UK

10,510

-1.37%↓

GSK

1,406

-1.37%↓

Indivior PLC

Затворен

1,156 -0.6

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1136

Максимум

1168

Ключови измерители

By Trading Economics

Приходи

-19M

47M

Продажби

-33M

266M

P/E

Средно за сектора

330

39.564

Марж на печалбата

17.669

Служители

1,030

EBITDA

-30M

76M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+14.46% upside

Дивиденти

By Dow Jones

Следващи печалби

24.07.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

584M

1.4B

Предишно отваряне

1156.6

Предишно затваряне

1156

Indivior PLC Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

14.07.2025 г., 22:07 ч. UTC

Значими двигатели на пазара

Trade Desk Rises on S&P 500 Inclusion

14.07.2025 г., 17:06 ч. UTC

Значими двигатели на пазара

Crypto Assets Rally Ahead of Possible U.S. Legislation

14.07.2025 г., 16:47 ч. UTC

Придобивния, сливания и поглъщания

NatWest to Sell Stake in Permanent TSB

14.07.2025 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Rise as Yen Weakens -- Market Talk

14.07.2025 г., 23:38 ч. UTC

Пазарно говорене

Gold Edges Higher Ahead of U.S. CPI Data -- Market Talk

14.07.2025 г., 23:37 ч. UTC

Пазарно говорене

ANZ's Institutional Earnings Likely to Weigh on Outlook -- Market Talk

14.07.2025 г., 23:29 ч. UTC

Пазарно говорене

South32 Bull Eyes Possible Last-Minute Power Deal for Mozal -- Market Talk

14.07.2025 г., 23:29 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

14.07.2025 г., 23:02 ч. UTC

Печалби

China Vanke: Additional Provision for Asset Impairment Also Among Factors Weighing on Results >000002.SZ

14.07.2025 г., 23:02 ч. UTC

Печалби

China Vanke: Weakness in Overall China Real-Estate Sector Weighed on Results >000002.SZ

14.07.2025 г., 23:02 ч. UTC

Печалби

China Vanke 1H Loss Was CNY9.85B >000002.SZ

14.07.2025 г., 23:01 ч. UTC

Печалби

China Vanke Sees 1H Loss CNY10.0B-Loss CNY12.0B >000002.SZ

14.07.2025 г., 23:01 ч. UTC

Печалби

China Vanke Expects 1H Loss to Widen >000002.SZ

14.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

14.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

14.07.2025 г., 20:07 ч. UTC

Пазарно говорене

Cloud Computing Giants Will Be the Winner from Software's Loss -- Market Talk

14.07.2025 г., 20:05 ч. UTC

Пазарно говорене

Adobe and Salesforce May Struggle to Keep Up With AI Agents -- Market Talk

14.07.2025 г., 19:11 ч. UTC

Пазарно говорене

Oil Retreats Despite Trump Threats of Russia Sanctions -- Market Talk

14.07.2025 г., 19:09 ч. UTC

Пазарно говорене

Gold Breaks a 3-Day Win Streak -- Market Talk

14.07.2025 г., 18:59 ч. UTC

Пазарно говорене

Hotter Weather Outlook, LNG Flows Boost U.S. Natural Gas -- Market Talk

14.07.2025 г., 18:30 ч. UTC

Придобивния, сливания и поглъщания

Synopsys Buy of Ansys Gets China OK. The $35 Billion Deal Is Set to Close. -- Barrons.com

14.07.2025 г., 18:25 ч. UTC

Пазарно говорене

Dollar Gains, Treasury Yields Lose Steam as Trump Threatens Russia -- Market Talk

14.07.2025 г., 18:25 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

14.07.2025 г., 16:59 ч. UTC

Пазарно говорене

Goldman Sachs Lifts 2H25 Crude Price Views -- Market Talk

14.07.2025 г., 16:53 ч. UTC

Горещи акции

Stocks to Watch Monday: Kenvue, Tesla, Synopsys, Robinhood -- WSJ

14.07.2025 г., 16:27 ч. UTC

Пазарно говорене

Oil Falls as Investors Monitor U.S.-EU Trade, Trump's Russia Sanction Threats -- Market Talk

14.07.2025 г., 16:20 ч. UTC

Пазарно говорене
Печалби

Auto & Transport Roundup: Market Talk

14.07.2025 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

14.07.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

14.07.2025 г., 16:12 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Indivior PLC Прогноза

Ценова цел

By TipRanks

14.46% нагоре

12-месечна прогноза

Среден 1,335.76 GBX  14.46%

Висок 1,637.669 GBX

Нисък 967.713 GBX

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Indivior PLC през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

4 ratings

4

Купи

0

Задържане

0

Продай

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Indivior PLC

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.